Business Wire

CA-TULA-TECHNOLOGY

29.4.2021 09:02:12 CEST | Business Wire | Press release

Share
Tula’s DMD™ Improves Electric Motor Efficiency While Reducing Rare Earth Materials in Battery Electric Vehicles

Tula Technology, Inc. , a leader in propulsion efficiency, reported today at the International Vienna Motor Symposium that their product Dynamic Motor Drive (DMD™) mitigates efficiency losses of electric motors while significantly reducing reliance on rare-earth materials. DMD’s application to electric vehicle motors has the potential to increase range while using less energy.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210429005254/en/

Improving the efficiency of the powertrain is key to reducing the energy consumed by an electric vehicle. Electric motors equipped with rare earth magnets can exceed 90% efficiency at peak performance; however, real-world driving conditions often reduce motor efficiency to approximately 70-85%, far below the peak. The patented DMD pulse density strategy mitigates efficiency losses through improvements in control software. Tula has simulated the DMD concept and projects efficiency improvements of 2.5% on the Worldwide Harmonized Light Vehicle Test Procedure (WLTP) cycle for an average electric vehicle. These improvements increase driving range while lowering total energy consumed. DMD is cost-effective, software-driven and does not require hardware changes to the motor or vehicle. Additionally, DMD avoids many of the rare earth material challenges including escalating future costs, limited supply and sourcing risks.

R. Scott Bailey , president and CEO of Tula Technology, commented, “By 2040, more than half of all passenger vehicles sold globally will be electric*. Tula’s Dynamic Motor Drive technology delivers high-value efficiency improvement to the full spectrum of electrification applications. With DMD, we can take a synchronous reluctance motor with low permanent magnet content and increase its efficiency to a level nearly comparable to a full permanent magnet motor. This reduces reliance on rare earth metals, which translates to lower cost and greater supply chain security. We are very excited about our DMD results, and our team is ready to work with partners and customers to optimize motor system performance in the transportation, industrial and power generation industries.”

Tula’s first product, Dynamic Skip Fire (DSF®), is an advanced cylinder deactivation control strategy that has been shown to significantly reduce CO2 emissions in gasoline engines and has been in production since 2018 with more than one million vehicles on the road. As presented jointly with Cummins at the Society of Automotive Engineers World Congress this year, the diesel application of DSF, Diesel Dynamic Skip Fire (dDSF™), was shown to reduce nitrogen oxide emissions by 74% and CO2 emissions by 5% in a Class 8 truck operating in a low-load cycle. DMD takes Tula’s control strategy to electric motors and has the potential to improve efficiency beyond electric vehicles into other modes of transportation, propulsion, and power conversion.

*Electric Vehicle Outlook 2020, Bloomberg NEF

About Tula Technology, Inc.

Silicon Valley-based Tula Technology provides innovative award-winning software controls to optimize propulsion efficiency and emissions across the mobility spectrum, including gasoline-powered, diesel, alternative fuel, hybrid, and electric vehicles. Tula’s culture of innovation has resulted in breakthrough technology and a robust global patent portfolio of more than 340 patents issued and pending. Tula Technology is a privately held company backed by Sequoia Capital, Sigma Partners, Khosla Ventures, GM Ventures, BorgWarner and Franklin Templeton. More information is available at www.tulatech.com .

Editor’s note: Tula (DMD) video introduces Tula, current electric vehicle motor technology challenges and DMD™ concept, operation and benefits. https://youtu.be/Zx74lfvOZ-U

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

GE HealthCare Announces First Patient Dosed in Phase 2/3 LUMINA Trial for Manganese-Based MRI Contrast Agent Under FDA Fast Track Designation, Further Advancing Its Innovation Pipeline of Novel Imaging Agents23.4.2026 13:29:00 CEST | Press release

Mangaciclanol, if approved, could transform contrast-enhanced MR imaging by offering an alternative to - or even replacing - gadolinium-based MRI agentsA manganese-based MRI contrast agent could address concerns with gadolinium-based contrast agents around retention in the body, security of supply, and the environment, with mangaciclanol’s clinical development under FDA Fast Track designationThe program demonstrates GE HealthCare’s commitment to advancing novel imaging agents to address unmet patient needs GE HealthCare (Nasdaq: GEHC) today announced the first patient has been dosed in the international, multi-center Phase 2/3 LUMINA clinical trial of its manganese-based magnetic resonance imaging (MRI) contrast agent, mangaciclanol, at Mayo Clinic in Rochester, Minnesota. Mangaciclanol, if approved, could offer an alternative to – or even replace – gadolinium-based MRI contrast agents, the current standard of care. The investigational agent has been granted Fast Track designation by t

Croma Pharma Launches AI-Driven Tech Venture to Revolutionize Aesthetic Medicine via Clinicore Platform23.4.2026 13:13:00 CEST | Press release

New structure to drive AI-powered innovation and international expansion Croma Pharma has launched a strategic joint venture to accelerate the development of Clinicore, its premium digital solution for aesthetic practices. This dedicated entity will focus on scaling the next generation of the platform while ensuring full continuity for existing users. Clinicore: Elevating Practice Excellence through AI Clinicore is a specialized SaaS (Software as a Service) solution designed to optimize the daily operations of aesthetic clinics. By automating patient management, scheduling, and administrative workflows, it enables healthcare professionals to focus entirely on patient care. A core element of the new strategy is a strong focus on Artificial Intelligence. Clinicore is evolving into a smart assistant, utilizing AI-driven features for automated treatment documentation, intelligent onboarding tools, and advanced process automation. This ensures that clinics can operate at maximum efficiency

NIQ Launches Commerce Lab to Build the Data and Measurement Layer for AI-Driven Commerce23.4.2026 13:00:00 CEST | Press release

NielsenIQ (NYSE: NIQ) today announced the launch of NIQ Commerce Lab, where the company is building the technology infrastructure for AI-driven commerce. The Lab will develop the data platforms, APIs, and measurement systems that power how products are discovered, evaluated, and purchased in AI-mediated environments. This includes what the industry often refers to as agentic commerce, but extends across quick commerce, social commerce, and other emerging channels—where AI is becoming the common layer shaping how consumers navigate choices and how decisions are made in real time. AI systems are rapidly moving from supporting decisions to making them—playing an increasingly central role in how commerce operates. Their effectiveness depends on the intelligence behind them. AI is Becoming the Operating Layer of Global Commerce NIQ ensures that the intelligence behind these systems is accurate, complete, and grounded in real-world behavior—reflecting how consumers actually buy, what product

Chiesi Reports Strong FY2025 Financial and Sustainability Results and Announces Leadership Transition Highlights23.4.2026 12:10:00 CEST | Press release

Strong FY2025 financial and sustainability results; leadership transition will support continuity and long-term growth Revenue up 8.2% to €3.6bn with double-digit growth in Rare Diseases and U.S. market Air sales at €1.886bn, growing 3.9% vs. 2024 - Care sales at €904m growing 13.3% vs. 2024 - Rare sales at €906m, growing 22.3% vs. 2024 Giuseppe Accogli leaving to pursue another opportunity, Group CFO Jean-Marc Bellemin named Interim CEO while new CEO search is underway Record €885m Research & Development (R&D) investment underscores continued commitment to innovation across respiratory, rare disease and specialty care Sustainability leadership further strengthened through B Corp recertification and progress on Carbon Minimal Inhaler (CMI) innovation Chiesi Group (“Chiesi”), an international research‑focused biopharmaceutical company and certified B Corp, today announced its financial results for the year ended 31 December 2025. Chiesi reported €3.625 billion in consolidated revenues,

REPLY S.p.A.: Shareholders’ Meeting Approves the 2025 Financial Statements23.4.2026 12:05:00 CEST | Press release

Consolidated turnover of €2,483.6 million (€2,300.5 million in 2024);Group net profits of €250.9 million (€211.1 million in 2024).Approval of the proposal to distribute a dividend of €1.35 per share.Approval of the plan for the purchase and/or disposal of treasury shares. The General Shareholders’ meeting of Reply S.p.A. [EXM, STAR: REY] held today approved the Financial Statements for the financial year 2025, confirming the distribution of a gross dividend of €1.35 per share. The dividend will be paid on 20 May 2026, with dividend date set on 18 May 2026 (record date on 19 May 2026). Approval of the 2025 financial statements The Reply Group closed the 2025 financial year with a consolidated turnover of €2,483.6 million, recording a 8.0% increase compared to €2,300.5 million in 2024. Consolidated EBITDA was €467.6 million, up 13.9% compared to €410.6 million recorded for the year 2024. EBIT, from January to December, was €397.1 million, up 18.5% compared to €330.4 million recorded for

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye